Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

[Preprint]. 2023 Oct 2:2023.09.29.560199. [Version 1] doi: 10.1101/2023.09.29.560199

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.

PMC Copyright notice

Figure 6: — (A) Systemic anti-PD-1 treated for 5 weeks duration. Includes mice that developed tumors within 35 to 77 (Arf6^WT) days or 49 to 91 (Arf6^f/f) days after Cre injection. Kaplan-Meier log-rank test. D/C= discontinued treatment. (B) Association of ICB treatment outcome with mRNA levels of ARF6, CYTH1 in transcriptomes of pretreatment melanoma biopsies (CancerImmu expression analysis, aggregated data from n=10 queried melanoma clinical studies, adjusted p-values, Benjamini and Hochberg procedure, LR=likelihood ratio with df=1). (C) Proposed model of ARF6-mediated rheostatic control of ICB treatment outcomes. See also Figure S6.